ArticleUnited European gastroenterology journal2026
Cirrhosis Impairs Reconstitution of the Circulating T-Lymphocyte Compartment After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
Article in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundDirect-acting antivirals (DAAs) achieve sustained virological response (SVR) in over 95% of patients with chronic hepatitis C virus (HCV) infection. Although viral eradication allows partial immune restoration, it remains unclear whether established cirrhosis limits recovery of the circulating T lymphocyte compartment after SVR.
methodsWe performed a phenotypic and functional analysis of circulating T-helper (Th) and T-cytotoxic (Tc) lymphocytes in patients with chronic HCV infection without fibrosis (HCV-NoF, n = 21) or with cirrhosis (HCV-cirrhosis, n = 20), as well as in alcohol-related cirrhosis (AL-cirrhosis, n = 12) and healthy controls (HC, n = 12). HCV patients were evaluated at baseline and 14 weeks after SVR following DAA therapy. Peripheral blood mononuclear cells were analysed by flow cytometry to quantify T lymphocyte subsets, cytokine production (IFNγ, IL-17), and regulatory T lymphocytes (CD25
resultsHCV infection was associated with marked Tc lymphopenia and selective depletion of naïve Th lymphocytes, regardless of fibrosis stage. These alterations were exacerbated in cirrhosis, particularly in decompensated disease, and closely resembled those observed in AL-cirrhosis. After SVR, HCV-NoF patients showed normalization of Tc counts, redistribution of Tc subsets, and restoration of Th1/Th17 balance and IFNγ/IL-17 profiles. In contrast, HCV-cirrhosis patients exhibited minimal immune recovery, with persistent Th and Tc lymphopenia, sustained depletion of naïve and central memory T lymphocyte subsets, and ongoing inflammatory cytokine skewing. CD25high Treg frequencies increased after SVR in both HCV groups but remained below HC levels, with normalization of chemokine receptor expression occurring only in HCV-NoF patients. DISCUSSION: Cirrhosis profoundly constrains immune reconstitution after HCV cure, limiting post-treatment T-cell recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.